{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "adds_modification",
    "modifications" : [ {
      "position" : "1c",
      "modification_type" : "glycosylation"
    } ],
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "be:Hemoglobin",
      "entity_text" : "hemoglobin",
      "entity_type" : "protein"
    },
    "is_direct" : false,
    "hypothesis_information" : false,
    "context" : {
      "TissueType" : [ "tissuelist:TS-0800" ],
      "Species" : [ "taxonomy:9606" ]
    }
  },
  "verbose_text" : "Initial clinical trials have shown that dulaglutide treatment results in dose dependent reductions in fasting plasma glucose (FPG), postprandial plasma glucose, and glycosylated hemoglobin A 1c (HbA 1c).",
  "reading_complete" : "2020-07-28T15:20:32Z",
  "reader_type" : "machine",
  "reading_started" : "2020-07-28T15:14:46Z",
  "trigger" : "glycosylated",
  "evidence" : [ "glycosylated hemoglobin A 1c  (HbA 1c" ],
  "pmc_id" : "4113177",
  "score" : 0
}